Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis by Wenjie Liu, Gengwei Huo, Gengwei Huo, Peng Chen

Get full text

Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features by Gengwei Huo, Gengwei Huo, Wenjie Liu, Peng Chen

Get full text

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis by Gengwei Huo, Gengwei Huo, Wenjie Liu, Shuo Kang, Peng Chen

Get full text

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer by Wenjie Liu, Wenjie Liu, Wenjie Liu, Wenjie Liu, Gengwei Huo, Gengwei Huo, Gengwei Huo, Gengwei Huo, Peng Chen, Peng Chen, Peng Chen, Peng Chen

Get full text

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States by Wenjie Liu, Gengwei Huo, Peng Chen

Get full text

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics by Wenjie Liu, Gengwei Huo, Peng Chen

Get full text

Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis by Gengwei Huo, Wenjie Liu, Peng Chen

Get full text

Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States by Gengwei Huo, Ying Song, Wenjie Liu, Xuchen Cao, Peng Chen

Get full text

High incidence and reversible bradycardia events following alectinib initiation by Dongqi Yuan, Fuyi Zhu, Ran Zuo, Yu Wang, Gengwei Huo, Jinfang Cui, Ping Yue, Peng Chen

Get full text